Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience

Abstract Background and Aim Saroglitazar, a dual PPAR α/γ agonist, is useful in management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of saroglitazar in NAFLD patients with or without diabetes including compensated cirrhosis. Methods Patients, started on saroglitazar...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Sujit Chaudhuri, Agnibha Dutta, Sunil Baran Das Chakraborty
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2023-03-01
Schriftenreihe:	JGH Open
Schlagworte:	cirrhosis fibrosis NAFLD saroglitazar
Online-Zugang:	https://doi.org/10.1002/jgh3.12878
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!